Cover Image

Outcome of acute respiratory distress syndrome requiring extracorporeal membrane oxygenation in Covid-19 or influenza: a single-center registry study

Veno-venous extracorporeal membrane oxygenation (V-V ECMO) is used to sustain blood oxygenation and decarboxylation in severe acute respiratory distress syndrome (ARDS). It is under debate if V-V ECMO is as appropriate for coronavirus disease 2019 (Covid-19) ARDS as it is for influenza. In this retr...

Full description

Saved in:
Bibliographic Details
Main Authors: Jäckel, Markus (Author) , Rilinger, Jonathan (Author) , Lang, Corinna Nadine (Author) , Zotzmann, Viviane (Author) , Kaier, Klaus (Author) , Stachon, Peter (Author) , Biever, Paul Marc (Author) , Wengenmayer, Tobias (Author) , Duerschmied, Daniel (Author) , Bode, Christoph (Author) , Staudacher, Dawid Leander (Author) , Supady, Alexander (Author)
Format: Article (Journal)
Language:English
Published: June 2021
In: Artificial organs
Year: 2021, Volume: 45, Issue: 6, Pages: 593-601
ISSN:1525-1594
DOI:10.1111/aor.13865
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1111/aor.13865
Verlag, kostenfrei, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/aor.13865
Get full text
Author Notes:Markus Jäckel, Jonathan Rilinger, Corinna Nadine Lang, Viviane Zotzmann, Klaus Kaier, Peter Stachon, Paul Marc Biever, Tobias Wengenmayer, Daniel Duerschmied, Christoph Bode, Dawid Leander Staudacher, Alexander Supady
Description
Summary:Veno-venous extracorporeal membrane oxygenation (V-V ECMO) is used to sustain blood oxygenation and decarboxylation in severe acute respiratory distress syndrome (ARDS). It is under debate if V-V ECMO is as appropriate for coronavirus disease 2019 (Covid-19) ARDS as it is for influenza. In this retrospective study, we analyzed all patients with confirmed SARS-CoV-2 or influenza A/B infection, ARDS and V-V ECMO, treated at our medical intensive care unit (ICU) between October 2010 and June 2020. Baseline and procedural characteristics as well as survival 30 days after ECMO cannulation were analyzed. A total of 62 V-V ECMO patients were included (15 with Covid-19 and 47 with influenza). Both groups had similar baseline characteristics at cannulation. Thirty days after ECMO cannulation, 13.3% of all patients with Covid-19 were discharged alive from our ICU compared to 44.7% with influenza (P = .03). Patients with Covid-19 had fewer ECMO-free days (0 (0-9.7) days vs. 13.2 (0-22.1) days; P = .05). Cumulative incidences of 30-day-survival showed no significant differences (48.6% in Covid-19 patients, 63.7% in influenza patients; P = .23). ICU treatment duration was significantly longer in ARDS patients with V-V ECMO for Covid-19 compared to influenza. Thirty-day mortality was higher in Covid-19, but not significant.
Item Description:First published: 14 November 2020
Gesehen am 04.01.2024
Physical Description:Online Resource
ISSN:1525-1594
DOI:10.1111/aor.13865

Similar Items